

S 2677

Consumer Access to Prescription Drugs Improvement Act of 2002

Congress: 107 (2001–2003, Ended)

Chamber: Senate

Policy Area: Health

Introduced: Jun 25, 2002

Current Status: Read twice and referred to the Committee on Finance. (text of measure as introduced: CR S6020-6025)

Latest Action: Read twice and referred to the Committee on Finance. (text of measure as introduced: CR S6020-6025)
(Jun 25, 2002)

Official Text: <https://www.congress.gov/bill/107th-congress/senate-bill/2677>

Sponsor

Name: Sen. Rockefeller, John D., IV [D-WV]

Party: Democratic • **State:** WV • **Chamber:** Senate

Cosponsors

No cosponsors are listed for this bill.

Committee Activity

Committee	Chamber	Activity	Date
Finance Committee	Senate	Referred To	Jun 25, 2002

Subjects & Policy Tags

Policy Area:

Health

Related Bills

No related bills are listed.

Summary (as of Jun 25, 2002)

Consumer Access to Prescription Drugs Improvement Act of 2002 - Amends title XVIII (Medicare) of the Social Security Act to establish the Pharmaceutical Advisory Committee as part of the Medicare Payment Advisory Commission. Directs such Committee to review payment policies for drugs under the Medicare and Medicaid programs and make payment policy recommendations, including considering the effects of direct-to-consumer marketing and the use and barriers to use of generic drugs.

Focuses studies and requires guidance on physicians' and patients' understanding of the relative efficacy and effectiveness of drugs and biological products, particularly generic versions.

Amends the Federal Food, Drug, and Cosmetic Act to require the deposit into a Drug Reimbursement Fund of revenues earned by a patent holder during a period when a competitor was wrongfully enjoined from marketing a generic version.

Sets forth notice and publication requirements for agreements reached by a brand name drug company and a generic drug applicant concerning challenges to a patent certification.

Amends the title XVIII (Medicare) of the Social Security Act to include coverage for all oral anticancer drugs, regardless of the method of administration, under the Medicare current drug benefit. Requires the Medicaid Drug Use Review Program to provide for the distribution of generic drug samples of covered outpatient drugs to prescribers.

Addresses the relationship between prices charged for inpatient drugs at certain public hospitals and the best price exemptions established for the Medicaid Drug Rebate Program.

Requires that the national drug code for each drug be made available upon the publication of the upper payment limits for multiple source drugs under Medicaid.

Actions Timeline

- **Jun 25, 2002:** Introduced in Senate
- **Jun 25, 2002:** Sponsor introductory remarks on measure. (CR S6019-6020)
- **Jun 25, 2002:** Read twice and referred to the Committee on Finance. (text of measure as introduced: CR S6020-6025)